SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers

Christine Laronga, Stephen Becker, Patrice Watson, Betsy Gregory, Lisa Cazares, Henry T. Lynch, Roger R. Perry, George L. Wright, Richard R. Drake, O. John Semmes

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6-9 mos.) were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalDisease Markers
Volume19
Issue number4-5
StatePublished - 2003

Fingerprint

Ionization
Desorption
Lasers
Breast Neoplasms
Serum
Surgery
Proteins
Patient treatment
Oncology
Biomarkers
Mass spectrometry
Blood Proteins
Assays
Therapeutics
cyhalothrin
Mass Spectrometry
Technology
Mutation
Sentinel Lymph Node
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Clinical Biochemistry

Cite this

Laronga, C., Becker, S., Watson, P., Gregory, B., Cazares, L., Lynch, H. T., ... Semmes, O. J. (2003). SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Disease Markers, 19(4-5), 229-238.

SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. / Laronga, Christine; Becker, Stephen; Watson, Patrice; Gregory, Betsy; Cazares, Lisa; Lynch, Henry T.; Perry, Roger R.; Wright, George L.; Drake, Richard R.; Semmes, O. John.

In: Disease Markers, Vol. 19, No. 4-5, 2003, p. 229-238.

Research output: Contribution to journalArticle

Laronga, C, Becker, S, Watson, P, Gregory, B, Cazares, L, Lynch, HT, Perry, RR, Wright, GL, Drake, RR & Semmes, OJ 2003, 'SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers', Disease Markers, vol. 19, no. 4-5, pp. 229-238.
Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch HT et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Disease Markers. 2003;19(4-5):229-238.
Laronga, Christine ; Becker, Stephen ; Watson, Patrice ; Gregory, Betsy ; Cazares, Lisa ; Lynch, Henry T. ; Perry, Roger R. ; Wright, George L. ; Drake, Richard R. ; Semmes, O. John. / SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. In: Disease Markers. 2003 ; Vol. 19, No. 4-5. pp. 229-238.
@article{f468687f6296400da5d03d3aae912bdb,
title = "SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers",
abstract = "Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6-9 mos.) were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.",
author = "Christine Laronga and Stephen Becker and Patrice Watson and Betsy Gregory and Lisa Cazares and Lynch, {Henry T.} and Perry, {Roger R.} and Wright, {George L.} and Drake, {Richard R.} and Semmes, {O. John}",
year = "2003",
language = "English",
volume = "19",
pages = "229--238",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",
number = "4-5",

}

TY - JOUR

T1 - SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers

AU - Laronga, Christine

AU - Becker, Stephen

AU - Watson, Patrice

AU - Gregory, Betsy

AU - Cazares, Lisa

AU - Lynch, Henry T.

AU - Perry, Roger R.

AU - Wright, George L.

AU - Drake, Richard R.

AU - Semmes, O. John

PY - 2003

Y1 - 2003

N2 - Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6-9 mos.) were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.

AB - Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6-9 mos.) were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=3042715627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042715627&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 229

EP - 238

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

IS - 4-5

ER -